Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

NCT06650501

Status	RECRUITING
Phase	Phase 4
Sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Enrollment	300 participants

Key Eligibility Criteria

Inclusion (1)

- Patient is taking (or will imminently start taking) an oral Xa inhibitor (e.g., apixaban, edoxaban, rivaroxaban) for: stroke prevention in atrial fibrillation, treatment or secondary prevention of deep venous thrombosis or pulmonary embolism, prevention of VTE in patients who have undergone elective total hip or total knee replacement surgery provided there are 30 or more days of planned treatment remaining at the time of enrolment.

Exclusion (8)

- Active bleeding as determine by the site investigator after discussion with the treating team (patient may remain eligible for up to 120 hours from platform entry if condition is resolved and antithrombotic therapy is resumed)
- Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days
- Known pregnancy (with testing available for women with childbearing potential)
- Known use of dabigatran within last month
- Allergy to dabigatran

... and 3 more (see full listing online)

Locations (1 total)

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada